← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
JXG
JX Luxventure Group Inc.
Valuation N/A
Industrials Risk 44 · Elevated
Price$8.95
Model IV—
P/IV—
Limited data — see page
JYD
Jayud Global Logistics Ltd
Valuation N/A
Industrials Risk 39 · Moderate
Price$0.82
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
JZ
Jianzhi Education Technology Group Co Ltd
Valuation N/A
Consumer Defensive Risk 41 · Elevated
Price$0.76
Model IV—
P/IV—
Market implies +41.8%/yr vs model +15.0% · above model
KALA
KALA BIO, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.57
Model IV—
P/IV—
Market implies +6.2%/yr vs model +15.0% · below model
KALU
KAISER ALUMINUM CORP
Valuation N/A
Basic Materials Risk 65 · High
Price$149.06
Model IV—
P/IV—
Market implies +28.3%/yr vs model +6.1% · above model
KALV
KalVista Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 49 · Elevated
Price$27.00
Model IV—
P/IV—
Market implies +34.7%/yr vs model +15.0% · above model
KAPA
Kairos Pharma, LTD.
Valuation N/A
Healthcare Risk 45 · Elevated
Price$1.76
Model IV—
P/IV—
Limited data — see page
KARO
Karooooo Ltd.
Valuation N/A
Technology Risk 50 · Elevated
Price$67.23
Model IV—
P/IV—
Limited data — see page
KB
KB Financial Group Inc.
Valuation N/A
Financial Services Risk 30 · Moderate
Price$132.01
Model IV—
P/IV—
Limited data — see page
KBDC
Kayne Anderson BDC, Inc.
Valuation N/A
Unknown Risk 27 · Moderate
Price$13.03
Model IV—
P/IV—
Limited data — see page
KBON
Karbon Capital Partners Corp.
Valuation N/A
Financial Services Risk 36 · Moderate
Price$10.10
Model IV—
P/IV—
Limited data — see page
KC
Kingsoft Cloud Holdings Ltd
Valuation N/A
Technology Risk 40 · Elevated
Price$9.96
Model IV—
P/IV—
Market implies +24.5%/yr vs model +3.0% · above model
KCHV
Kochav Defense Acquisition Corp.
Valuation N/A
Financial Services
Price$10.45
Model IV—
P/IV—
Limited data — see page
KCHVR
Kochav Defense Acquisition Corp.
Valuation N/A
Financial Services
Price$0.11
Model IV—
P/IV—
Limited data — see page
KDK
Kodiak AI, Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$3.74
Model IV—
P/IV—
Market implies +53.9%/yr vs model +15.0% · above model
KDKRW
Kodiak AI, Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$0.60
Model IV—
P/IV—
Market implies +32.0%/yr vs model +15.0% · above model
KEEL
Keel Infrastructure Corp.
Valuation N/A
Financial Services Risk 45 · Elevated
Price$3.57
Model IV—
P/IV—
Market implies +66.9%/yr vs model +15.0% · above model
KF
KOREA FUND INC
Valuation N/A
Unknown
Price$67.98
Model IV—
P/IV—
Limited data — see page
KFII
K&F GROWTH ACQUISITION CORP. II
Valuation N/A
Financial Services
Price$10.65
Model IV—
P/IV—
Limited data — see page
KFIIR
K&F GROWTH ACQUISITION CORP. II
Valuation N/A
Financial Services
Price$0.09
Model IV—
P/IV—
Limited data — see page
KGEI
Kolibri Global Energy Inc.
Valuation N/A
Energy Risk 29 · Moderate
Price$6.57
Model IV—
P/IV—
Limited data — see page
KIDZ
Classover Holdings, Inc.
Valuation N/A
Consumer Defensive Risk 42 · Elevated
Price$3.38
Model IV—
P/IV—
Market implies +16.2%/yr vs model +2.0% · above model
KIO
KKR Income Opportunities Fund
Valuation N/A
Unknown
Price$10.95
Model IV—
P/IV—
Limited data — see page
KITT
Nauticus Robotics, Inc.
Valuation N/A
Industrials Risk 46 · Elevated
Price$0.66
Model IV—
P/IV—
Market implies +10.1%/yr vs model +2.0% · above model
KLAR
Klarna Group plc
Valuation N/A
Financial Services Risk 31 · Moderate
Price$13.83
Model IV—
P/IV—
Limited data — see page
KLIC
KULICKE & SOFFA INDUSTRIES INC
Valuation N/A
Technology Risk 44 · Elevated
Price$86.13
Model IV—
P/IV—
Market implies +36.1%/yr vs model -5.7% · above model
KLRA
Kailera Therapeutics, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$13.75
Model IV—
P/IV—
Limited data — see page
KLRS
Kalaris Therapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$3.38
Model IV—
P/IV—
Limited data — see page
KMDA
KAMADA LTD
Valuation N/A
Healthcare Risk 36 · Moderate
Price$7.92
Model IV—
P/IV—
Limited data — see page
KN
Knowles Corp
Valuation N/A
Technology Risk 42 · Elevated
Price$36.92
Model IV—
P/IV—
Market implies +28.9%/yr vs model +2.0% · above model
KNOP
KNOT Offshore Partners LP
Valuation N/A
Industrials
Price$11.23
Model IV—
P/IV—
Limited data — see page
KNRX
KNOREX LTD.
Valuation N/A
Technology Risk 42 · Elevated
Price$0.34
Model IV—
P/IV—
Limited data — see page
KOD
Kodiak Sciences Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$32.89
Model IV—
P/IV—
Limited data — see page
KOF
COCA COLA FEMSA SAB DE CV
Valuation N/A
Consumer Defensive
Price$110.71
Model IV—
P/IV—
Limited data — see page
KOPN
KOPIN CORP
Valuation N/A
Technology Risk 42 · Elevated
Price$4.34
Model IV—
P/IV—
Market implies +77.9%/yr vs model +2.0% · above model
KOYN
CSLM Digital Asset Acquisition Corp III, Ltd
Valuation N/A
Financial Services
Price$10.23
Model IV—
P/IV—
Limited data — see page
KPET
KPET Ultra Paceline Corp
Valuation N/A
Financial Services
Price$9.98
Model IV—
P/IV—
Limited data — see page
KPRX
KIORA PHARMACEUTICALS INC
Valuation N/A
Healthcare Risk 46 · Elevated
Price$2.65
Model IV—
P/IV—
Market implies -4.2%/yr vs model +15.0% · below model
KPTI
Karyopharm Therapeutics Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.54
Model IV—
P/IV—
Limited data — see page
KRAQ
KRAKacquisition Corp
Valuation N/A
Financial Services Risk 40 · Elevated
Price$10.04
Model IV—
P/IV—
Limited data — see page
KRKR
36Kr Holdings Inc.
Valuation N/A
Technology
Price$3.14
Model IV—
P/IV—
Limited data — see page
KRMN
Karman Holdings Inc.
Valuation N/A
Industrials Risk 43 · Elevated
Price$35.28
Model IV—
P/IV—
Market implies +36.5%/yr vs model +27.7% · above model
KRNT
Kornit Digital Ltd.
Valuation N/A
Industrials Risk 36 · Moderate
Price$16.05
Model IV—
P/IV—
Market implies +36.3%/yr vs model +2.0% · above model
KRP
Kimbell Royalty Partners, LP
Valuation N/A
Energy
Price$14.84
Model IV—
P/IV—
Limited data — see page
KRRO
Korro Bio, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$13.81
Model IV—
P/IV—
Market implies +95.2%/yr vs model +2.0% · above model
KRSP
Rice Acquisition Corp 3
Valuation N/A
Financial Services
Price$10.53
Model IV—
P/IV—
Limited data — see page
KSPI
Joint Stock Co Kaspi.kz
Valuation N/A
Technology Risk 41 · Elevated
Price$98.76
Model IV—
P/IV—
Limited data — see page
KT
KT CORP
Valuation N/A
Communication Services Risk 40 · Elevated
Price$19.97
Model IV—
P/IV—
Limited data — see page
KTF
DWS MUNICIPAL INCOME TRUST
Valuation N/A
Unknown
Price$8.46
Model IV—
P/IV—
Limited data — see page
KTH
STRUCTURED PRODUCTS CORP CORTS TR FOR PECO ENERGY CAP TR III
Valuation N/A
Financial Services
Price$28.37
Model IV—
P/IV—
Limited data — see page
KTN
STRUCTURED PRODUCTS CORP CRED ENHANCE CORTS TR FOR AON CAP A
Valuation N/A
Financial Services
Price$25.57
Model IV—
P/IV—
Limited data — see page
KTOS
KRATOS DEFENSE & SECURITY SOLUTIONS, INC.
Valuation N/A
Consumer Cyclical Risk 31 · Moderate
Price$47.58
Model IV—
P/IV—
Market implies +67.4%/yr vs model +8.0% · above model
KTTA
Pasithea Therapeutics Corp.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.51
Model IV—
P/IV—
Market implies +25.5%/yr vs model +15.0% · above model
KTWO
K2 Capital Acquisition Corp
Valuation N/A
Financial Services
Price$10.10
Model IV—
P/IV—
Limited data — see page
KTWOR
K2 Capital Acquisition Corp
Valuation N/A
Financial Services
Price$0.21
Model IV—
P/IV—
Limited data — see page
KURA
Kura Oncology, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$11.39
Model IV—
P/IV—
Market implies +40.3%/yr vs model +15.0% · above model
KVAC
Keen Vision Acquisition Corp.
Valuation N/A
Financial Services Risk 32 · Moderate
Price$12.01
Model IV—
P/IV—
Limited data — see page
KWM
K Wave Media Ltd.
Valuation N/A
Communication Services Risk 42 · Elevated
Price$1.33
Model IV—
P/IV—
Limited data — see page
KWY
KINGSWAY Corp
Valuation N/A
Financial Services Risk 55 · Elevated
Price$9.59
Model IV—
P/IV—
Limited data — see page
KXIN
Kaixin Holdings
Valuation N/A
Consumer Cyclical Risk 28 · Moderate
Price$1.05
Model IV—
P/IV—
Market implies +53.7%/yr vs model +2.0% · above model